Industry
Biotechnology
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Loading...
Open
41.13
Mkt cap
2B
Volume
358K
High
42.58
P/E Ratio
-18.18
52-wk high
45.23
Low
41.13
Div yield
N/A
52-wk low
23.14
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 12:54 pm
Portfolio Pulse from Benzinga Insights
October 11, 2024 | 1:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 11, 2024 | 10:47 am
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 12:42 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 2:46 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 1:10 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 11:59 am
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 8:20 pm
Portfolio Pulse from Benzinga Newsdesk
July 26, 2024 | 7:19 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.